MK-0616

Intervention1 paper1 findingPubChem 167312471

Outcomes

1

LDL-C

downin humans1High certainty

1 study

  1. MK-0616 decreases LDL-C in humans (-60.9 pp, -75.0 to -46.8).

    Reviewversus placebo in hypercholesterolaemia30 mg

    Comparative efficacy and safety of orally administered PCSK9 inhibitors in patients with Hypercholesterolaemia: a dose-stratified systematic review and network meta-analysis · Endocrine · 6 Oct 2026

LDL-C →

Latest

Nov 2025: 1Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 13

Related